Pharmacodynamics of Drugs Used in Parkinson’s Disease – PST05104 Pharmacology and Therapeutics
NTA Level 5 • Semester 1 • PST05104 Pharmacodynamics of Drugs Used in Parkinson's Disease Pharmacology and Therapeutics • Source Session/Topic 31 Full source-text version: all educational wording from the extracted learning source is retained; only presenter/tutor metadata and web-layout noise are removed, while formatting is improved for readability. Session 31: Pharmacodynamics of Drugs Used in Parkinson's Disease Total Session Time: 120 minutes Prerequisites None Learning Tasks By the end of this session students are expected to be able to: Describe mechanism of action of Drugs Used in Parkinson's Disease Describe drug interactions associated with Drugs Used in Parkinson's Disease Describe side effects of Drugs Used in Parkinson's Disease Describe contraindications of Drugs Used in Parkinson's Disease Resources Needed: Flip charts, marker pens, and masking tape Black/white board and chalk/whiteboard markers Computer and LCD projector SESSION OVERVIEW Step Time Activity/ Content Step Time Activity/ Content Step Time Method Content Method Method 1 1 05 minutes 05 minutes Presentation Introduction, Learning Tasks Introduction, Learning Tasks Introduction, Learning Tasks 2 2 45 minutes 45 minutes Presentation/ Mechanism of Action of Drugs Used in Mechanism of Action of Drugs Used in Mechanism of Action of Drugs Used in 2 2 45 minutes 45 minutes Buzzing Parkinson's Disease Parkinson's Disease Parkinson's Disease Buzzing Parkinson's Disease Parkinson's Disease Parkinson's Disease 3 3 20 minutes 20 minutes Presentation/ Drug Interactions Associated With Drugs Drug Interactions Associated With Drugs Drug Interactions Associated With Drugs 3 3 20 minutes 20 minutes brainstorming Used in Parkinson's Disease Used in Parkinson's Disease Used in Parkinson's Disease brainstorming Used in Parkinson's Disease Used in Parkinson's Disease Used in Parkinson's Disease 4 4 20 minutes 20 minutes Presentation Adverse Effects of Drugs Used in Parkinson's Adverse Effects of Drugs Used in Parkinson's Adverse Effects of Drugs Used in Parkinson's 4 4 20 minutes 20 minutes Presentation Disease Disease Disease Disease Disease Disease 5 5 20 minutes 20 minutes Presentation/ Contraindications of Drugs Used in Contraindications of Drugs Used in Contraindications of Drugs Used in 5 5 20 minutes 20 minutes Brainstorming Parkinson's Disease Parkinson's Disease Parkinson's Disease Brainstorming Parkinson's Disease Parkinson's Disease Parkinson's Disease PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics PST 05104 Pharmacology & Therapeutics 242 242 242 NTA Level 5 Semester 1 Facilitator Guide NTA Level 5 Semester 1 Facilitator Guide 6 05 minutes Presentation Key Points 7 05 minutes Presentation Evaluation PST 05104 Pharmacology & Therapeutics 243 NTA Level 5 Semester 1 Facilitator Guide SESSION CONTENTS STEP 1: Presentation of Session Title and Learning Tasks (5 minutes) READ or ASK students to read the learning objectives and clarify ASK students if they have any questions before continuing. STEP 2: Mechanism of Action of Drugs Used in Parkinson's Disease (45 minutes) Activity: Buzzing (5 minutes) ASK students to pair up and buzz on the following question for 2 minutes How do drugs Used in Parkinson's Disease produce their pharmacological effects? ALLOW few pairs to respond and let other pairs add on points not mentioned WRITE their response on the flip chart/board CLARIFY and SUMMARIZE by using the content below Parkinsonism is a progressive neurologic disorder of muscle movement, characterized by tremors, muscular rigidity, bradykinesia (slowness in initiating and carrying out voluntary movements), and postural and gait abnormalities. The cause of Parkinson's disease is unknown for most patients. The disease is correlated with a reduction in the activity of inhibitory dopaminergic neurons in the substantia nigra and corpus striatum parts-of the brain's basal ganglia system that are responsible for motor control. Mechanisms of drugs used for treatment of Parkinsonism are: Dopamine Precussors; Levodopa o Levodopa is a metabolic precursor of dopamine. o Cross blood brain barrier as it is readily taken up by the amino transport systems. o It restores dopamine levels in the extrapyramidal centers (substantia nigra) that atrophy in parkinsonism. o Required in high doses because the drug is decarboxylated to dopamine in the periphery by L-aromatic amino acid decarboxylase enzyme. o Since Parkinsonism results from insufficient dopamine in specific regions of the brain, attempts have been made to replenish the dopamine deficiency. Dopamine itself PST 05104 Pharmacology & Therapeutics 244 NTA Level 5 Semester 1 Facilitator Guide does not cross the blood-brain barrier, but its immediate precursor levodopa is readily transported into the CNS and is converted to dopamine in the brain Actions: Levodopa decreases rigidity, tremors and other symptoms of parkinsonism. Carbidopa The effects of levodopa on the CNS can be greatly enhanced by coadministering carbidopa, a dopamine decarboxylase inhibitor that does not cross the blood-brain barrier. Carbidopa diminishes the metabolism of levodopa in the GI tract and peripheral tissues; thus, it increases the availability of levodopa to the CNS. The addition of carbidopa lowers the dose of levodopa needed by 4- to 5- fold and, consequently, decreases the severity of the side effects of peripherally formed dopamine. Catechol-O-Methyl Transferase (COMT) Inhibitors: Entacapone and tolcapone COMT inhibitors increase the amount of dopamine available to the CNS. COMT is one of the two major enzymes involved in the metabolism of catecholamines (epinephrine, norepinephrine, and dopamine). Thus one of the ways COMT inhibitors increase dopamine is by inhibiting its breakdown. Monoamine oxidase B inhibitors (MAO B) Inhibitors: Selegiline and Rasagiline Selectively inhibit MAO-B which metabolizes dopamine more efficiently than NE and 5-HT. The net effect is an increase in brain dopamine levels. These drugs can be used in conjunction with L-dopa. Because selegiline and rasagiline selectively inhibit MAO-B, they are much less likely to produce a hypertensive reaction with cheese or other sources of tyramine than non-selective MAOIs, such as phenelzine. Dopamine Agonists: Bromocriptine The absorption and extent of first-pass metabolism of bromocriptine is highly variable, leading to wide fluctuations in plasma concentrations and variability in dose response. Dopamine agonists bind to dopamine receptors to produce actions similar to dopamine. The dopamine agonists used in Parkinson‘s disease have longer durations